Aurinia Pharmaceuticals (AUPH) Revenue (2015 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Revenue data on file, last reported at $77.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 24.4% year-over-year to $77.7 million; the trailing twelve-month figure through Mar 2026 stood at $298.3 million (up 20.62% YoY), and the FY2025 full-year result was $283.1 million, up 20.38% from the prior year.
• Revenue for Q1 2026 stood at $77.7 million, up from $77.1 million in the prior quarter.
• Across five years, Revenue topped out at $77.7 million in Q1 2026 and bottomed at $21.6 million in Q1 2022.
• The 5-year median for Revenue is $55.8 million (2022), against an average of $53.3 million.
• The widest annual swing landed in 2022, when Revenue surged 2265.97%; it then retreated 2.27% in 2023.
• A 5-year view of Revenue shows it stood at $28.4 million in 2022, then jumped by 58.59% to $45.1 million in 2023, then jumped by 32.76% to $59.9 million in 2024, then increased by 28.81% to $77.1 million in 2025, then advanced by 0.77% to $77.7 million in 2026.
• The last three Revenue figures came in at $77.7 million (Q1 2026), $77.1 million (Q4 2025), and $73.5 million (Q3 2025), per Business Quant data.

Peer Comparison